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Bisphosphonates are recommended in the treatment of osteoporosis and some cancers, in which case they prevent
the appearance of bone metastasis. The patients taking bisphosphonates are at increased risk of developing
bisphosphonate-related osteonecrosis of jaw (BRONJ) which is characterised by the presence of an un-healing
wound after dental surgery. BRONJ might represent an anti-angiogenic side effect. However, the real number of
patients with BRONJ might be higher than currently recorded. Considering the differential diagnosis which includes
various primary and secondary cancers, a correct histopathological diagnosis is very important. The morphological
criteria for diagnosis of BRONJ are highlighted in this material.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1813972972323288Bisphosphonates, derivates of pyrophosphates, have been
used traditionally to treat hypocalcaemia associated with
osteoporosis, multiple myeloma, Paget’s disease and
bone metastasis in which case they exert an additional
analgesic effect [1]. They bind to the mineralized bone
matrix and by acting upon the oscteoclasts inhibit bone
resorption. In addition they inhibit formation of new
osteoclasts, subsequently creating an unfavourable envir-
onment for bone metastasis development [2]. Preclinical
and clinical studies suggest that bisphosphonates are
able to prevent bone metastasis in a variety of cancers
such as breast, lung and prostate. Therefore, we could
expect that an increasing number of cancer patients will
be taking regularly and for extended periods of time
these pharmacological agents [3-5].
Although their value in clinical practice has been
proven, the patients taking bisphosphonates are at risk
of developing bisphosphonate-related osteonecrosis of
jaw BRONJ. By definition, BRONJ is characterised by
the presence of an un-healing wound in the maxillofacial
region with bone exposure, more than 8 weeks after
dental surgery. It seems that patients treated with* Correspondence: e_petcu@hotmail.com
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reproduction in any medium, provided the orintravenous bisphosphonates have an increased risk of
developing this condition. The incidence is reported to
be around 1 in 10,000 patients [6]. In our opinion, con-
sidering the large number of patients treated with
bisphosphonates, the number of BRONJ cases is largely
underestimated and could be significantly higher. A cor-
rect histopathological identification of this lesion is of
paramount importance since the differential diagnosis
includes numerous primary and metastatic tumours.
The biopsy of a BRONJ lesion demonstrates extensive
necrosis and inflammation with giant cells (Figure 1 and
Figure 2). It is widely accepted that CD105-positive ves-
sels suggest active angiogenesis. However, recent studies
conducted on human tissues have shown a significant
reduction in CD105-positive vessels in the mucoperios-
teal area near the BRONJ zone suggesting inhibition of
angiogenesis [7].
In vitro and in vivo studies have suggested that bispho-
sphonates might inhibit IGF-1 induced activation of PI-
3 K/Akt/mTOR pathways and have an anti-angiogenic
action via inhibition of IGF-1 induced VEGF expression
and HIF-1 alpha protein accumulation in MCF-7 cells.
[8]. Other studies conducted in mice have revealed that
zolendronic acid, a nitrogen-containing bisphosphonate
suppresses MMP-9 expression by infiltrating macro-
phages, decreasing the binding of VEGF to its receptor
on angiogenic endothelial cells [9]. In addition, a clinical
study conducted in patients with metastatic breasttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 BRONJ: Non-viable bone and extensive osteonecrosis.
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http://www.diagnosticpathology.org/content/7/1/78cancer, has revealed that zolendronic acid could exert an
anti-angiogenic effect by inducing a transient reduction
in VEGF, FGF-2 and MMP-2 [10]. Overall, the above
data strongly suggests that bisphosphonates elicit anti-
angiogenic effects through a variety of mechanisms that
could explain their anti-tumoral action.
In this context, BRONJ represents a frustrating com-
plication for many long-term cancer survivors and
osteoporosis patients. Currently, much debate remains
on the oetiopathogenesis and management of this condi-
tion. We do not know why this lesion appears only in
the jaw and maxillofacial area, although the treatment
with bisphosphonates is systemic. Mc Leod et al. (2012)
suggest that the high turnover of alveolar bone and ex-
posure of the jaw bone may explain the oetiopathogen-
esis of this condition [11]. However, for a better
understanding of this condition more histomorphome-
trical studies of the maxillary and jaw region should be
conducted in parallel with a thorough evaluation of theFigure 2 BRONJ: Chronic inflammation with multi-nucleated
giant cells.anti-angiogenic role of bisphosphonates in human tis-
sues and animal models. In conclusion, BRONJ repre-
sents a largely underestimated condition due probably to
the fact that not many cases are diagnosed accurately by
routine histopathology.
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